BioCryst downplays embarrassing error

A red-faced BioCryst Pharmaceuticals Inc. announced that an incorrect randomization key is responsible for Phase II data that were erroneously reported in February to be statistically significant.

"Obviously, it's very embarrassing for the company," BCRX Director of Corporate Development John Higgins told BioCentury. However, he said, the development timeline for the

Read the full 513 word article

How to gain access

Continue reading with a
two-week free trial.